Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 71.5%

Neg 0% Neu 71.5% Pos 0%

Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.